TERT and liver cancer: The need for clinical trials evaluating the efficacy of anti-telomerase compounds in the treatment of HCC has been recently prompted by preclinical studies showing that liver cancer cell lines have oncogenic addiction to TERT expression and that malignant phenotype may be reverted by anti-TERT antisense oligonucleotides treatment.